Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy
Brain · 04.11.2026 · 149 (11) · 3954-3967
DOI: 10.1093/brain/awag091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Brain, online erschienen am 06.03.2026. Verfasst von Yuanchu Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, tau Proteins, Extracellular Vesicles, Neurons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
The diagnosis of progressive supranuclear palsy (PSP) remains challenging, particularly in differentiating it from Parkinson’s disease (PD) at early stages. Circulating neuron-derived extracellular vesicles (NDEVs), providing a peripheral window into CNS pathology, might serve as promising biomarkers. A total of 188 participants were recruited from three centres. A discovery cohort [40 PSP patients, 36 PD patients and 31 healthy controls (HCs)] and a multicentre validation cohort (30 PSP patients, 27 PD patients and 24 HCs) were established. NDEVs containing total tau, 4R tau or phosphorylated tau (ptau181, ptau217, ptau231 and ptau396) in plasma samples were analysed using nano-scale flow cytometry. Multivariable logistic regression models were developed in the discovery cohort and strictly validated in the independent cohort using fixed model parameters. In the discovery cohort, the concentrations of tau-, 4R tau-, ptau181- and ptau217-containing NDEVs in PSP patients were significantly higher than those in HCs and PD patients, whereas ptau396-containing NDEVs showed elevation exclusively in PSP compared with HCs (PSP versus HCs: P < 0.001 for tau, P < 0.001 for 4R tau, P < 0.001 for ptau181, P = 0.008 for ptau217, and P = 0.009 for ptau396; PSP versus PD: P < 0.001 for tau, P < 0.001for4R tau, P = 0.029 for ptau181, and P = 0.003 for ptau217). An integrated model incorporating these biomarkers achieved an area under the curve (AUC) of 0.965 (90.0% sensitivity, 96.8% specificity) for distinguishing PSP from HCs and an AUC of 0.963 (87.5% sensitivity, 94.4% specificity) for distinguishing PSP from PD. In the validation cohort, the concentrations of tau-, 4R tau-, ptau181-, ptau217- and ptau396-containing NDEVs in plasma were significantly higher in PSP patients compared with HCs (PSP versus HCs: P < 0.001 for tau, 4R tau and ptau217, P = 0.03 for ptau181, and P = 0.017 for ptau396). Likewise, the concentrations of tau-, 4R tau-, ptau181- and ptau217- were higher in PSP patients than in PD patients (PSP versus PD: P < 0.001 for tau, 4R tau and ptau217, and P = 0.025 for ptau181). The integrated model yielded an AUC of 0.971 for distinguishing PSP from HCs and 0.990 for distinguishing PSP from PD. Notably, in early-stage patients, the integrated model achieved an AUC of 0.987 in differentiating early-stage PSP from PD. These findings indicate that plasma tau-species-containing NDEVs are promising biomarkers for PSP, offering high sensitivity and specificity for distinguishing PSP from both HCs and PD, particularly in early disease stages. Further large-scale, longitudinal studies are warranted to validate these findings fully and explore their role in PSP pathophysiology and progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
- China National Clinical Research Center for Neurological Diseases, Beijing 100070, China.
- Department of Neurology, Beijing Hospital, National Center of Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of…
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Department of Neurology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
- Department of Pathology, The First Affiliated Hospital and School of Medicine, Zhejiang University, Hangzhou 310003, China.
ORCID-Profile: Zhenwei Yu, Tao Feng
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
- China Postdoctoral Science Foundation
- Beijing Neurosurgical Institute
- Beijing Postdoctoral Research Foundation
Zitieren
APA
Zheng, Y., Cai, H., Kou, W., Liu, G., Wang, Y., Bai, J., Piao, Y., Liu, X., Zhu, X., Zhang, J., Yu, Z., & Feng, T. (2026). Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy. Brain, 149(11), 3954-3967. https://doi.org/10.1093/brain/awag091
Vancouver
Zheng Y, Cai H, Kou W, Liu G, Wang Y, Bai J, et al. Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy. Brain. 2026;149(11):3954-3967. doi:10.1093/brain/awag091
BibTeX
@article{Zheng2026,
author = {Zheng, Yuanchu and Cai, Huihui and Kou, Wenyi and Liu, Genliang and Wang, Yanlin and Bai, Jing and Piao, Yingshan and Liu, Xuedong and Zhu, Xiaodong and Zhang, Jing and Yu, Zhenwei and Feng, Tao},
title = {Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy},
journal = {Brain},
year = {2026},
volume = {149},
number = {11},
pages = {3954--3967},
doi = {10.1093/brain/awag091}
}
EUVIMED